Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Active not recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 115Brain Neoplasms 114Prostatic Neoplasms 101Neoplasm Metastasis 79Carcinoma, Hepatocellular 69Lung Neoplasms 67Pancreatic Neoplasms 64Breast Neoplasms 48Melanoma 37Carcinoma, Renal Cell 33Neoplasms 31Squamous Cell Carcinoma of Head and Neck 21Colorectal Neoplasms 20Liver Neoplasms 19Glioblastoma 18Small Cell Lung Carcinoma 14Head and Neck Neoplasms 14Sarcoma 11Kidney Neoplasms 11Glioma 10Recurrence 8Urinary Bladder Neoplasms 7Radiation Injuries 6Neuroma, Acoustic 6Cholangiocarcinoma 6Adenocarcinoma 6Uveal Melanoma 5Uterine Cervical Neoplasms 5Prostate Cancer Metastatic 5Ovarian Neoplasms 5

Interventions

luprolide acetate gel depot 1enzalutamide 1Triptorelin Pamoate 1Radiosurgery 1Leuprolide 1Goserelin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Castration-resistant Prostate Cancer Patients with Oligometastases × Radiosurgery × Clear all
NCT02685397 2024-12-04

PCS IX

Sir Mortimer B. Davis - Jewish General Hospital

Phase 2/3 Active not recruiting
102 enrolled
Genitourinary

Castration-resistant Prostate Cancer Patients with Oligometastases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡